Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 780 in its research report dated May 19, 2022.
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 590 in its research report dated May 19, 2022.
Near-term growth visibility is low due to a lack of major product launches, aggravating pricing erosion and input cost pressure for Lupin
Prabhudas Lilladher recommended accumulate rating on Lupin with a target price of Rs 950 in its research report February 07, 2022.
ICICI Direct recommended hold rating on Lupin with a target price of Rs 960 in its research report dated February 07, 2022.
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1210 in its research report dated December 20, 2021.
ICICI Direct recommended hold rating on Lupin with a target price of Rs 1015 in its research report dated December 14, 2021.
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 990 in its research report dated December 14, 2021.
Lupin guided for 16 percent EBITDA margin in H2 of FY22. While sequentially it indicates normalisation, given the elevated pricing pressure in the US market, execution will be closely monitored
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated August 11, 2021.
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 1040 in its research report dated August 11, 2021.
ICICI Direct recommended hold rating on Lupin with a target price of Rs 1025 in its research report dated August 12, 2021.
The management of Lupin is confident of scaling back $200 million quarterly revenue run rate for US market by Q3, but at the same time, alluded to overall EBITDA margin guidance of 16-17 per cent in FY22
Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility
In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1350 in its research report dated January 29, 2021.
Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1287 in its research report dated January 29, 2021.
ICICI Direct is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1165 in its research report dated January 29, 2021.
Motilal Oswal is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1180 in its research report dated January 30, 2021.
Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1350 in its research report dated January 25, 2021.
Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1212 in its research report dated November 06, 2020.
HDFC Securities is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1120 in its research report dated November 06, 2020.
ICICI Direct recommended hold rating on Lupin with a target price of Rs 985 in its research report dated November 06, 2020.
The possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin
Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1085 in its research report dated September 30, 2020.